Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A 19-year-old has been using finasteride and oral minoxidil without desired results for hair loss and is seeking where to get dutasteride prescribed online. Various online sources for hair loss treatments, including dutasteride and RU58841, were suggested.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

RU58841 combined with finasteride or dutasteride is more effective than RU58841 alone for hair loss. Users suggest combining these with minoxidil and microneedling for better results.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation is about someone who had success using retinol with minoxidil for hair growth, but experienced shedding with Retin A (tretinoin). They are asking if others have tried retinol with minoxidil and what their results were.

The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.

The conversation is about the availability of Breezula, a hair loss treatment, with speculation it might be released in 2022 or potentially never, as it's more effective than finasteride. No specific treatments were confirmed.

The conversation is about a product called FLEAVA, found in a Facebook ad, and whether it is effective or just another scam. One user believes it is likely a scam and mentions that such products usually don't compete with Minoxidil.

A satirical post jokes about a user meeting a doctor at the zoo who praises finasteride (Fin) for hair loss treatment, claiming it has a low side-effect profile and is effective. Replies include humorous disbelief, comparisons to other risks, and some personal accounts of side effects from Fin.

The user has maintained their hairline with finasteride for 5 years and saw no results from minoxidil. They are inquiring if tretinoin alone can cause hair regrowth.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

Some men have strong balding genetics that treatments like Dutasteride, Minoxidil, or Finasteride may not fully address. Early intervention is believed to help, but many accept hair loss without treatment.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

The user is considering adding castor, rosemary, and pumpkin oils to their current hair loss treatment of finasteride and minoxidil. They are unsure about the effectiveness of these oils.

The user had a detailed 3.5-hour consultation with Dr. Zarev for hair loss treatment, praising his meticulous approach and innovative techniques, and was prescribed topical finasteride and minoxidil. Other users agreed on Zarev's expertise, noting his long waiting list and the high quality of his work, with one surgery per week and a focus on individual patient care.

A user experimenting with quitting using Minoxidil and replacing it with Finasteride and Stemoxydine in order to keep hair loss gains, but other users warning the original poster of potential shedding. Another user suggested phasing out Minoxidil and replacing it with Finasteride and microneedling instead.

The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

Whether using both Fluridil and Alfatradiol together could be more effective than either one alone as a hair loss treatment, given their different mechanisms of action.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

A long-term finasteride user experienced side effects like sexual dysfunction, dry eyes, muscle weakness, and brain fog, which improved when they stopped the medication. They decided to stop finasteride again, questioning if maintaining hair was worth the negative impact on their well-being.

A user takes 5mg oral minoxidil, oral dutasteride, topical tretinoin, stemoxydine, topical minoxidil, and uses dermarolling for hair loss but sees less impressive, patchy regrowth compared to others. Another person suggests some online results may be enhanced with hair fibers, not just medication.